News Breaks |
|
|
| November 11, 2012 |
| 12:40 EDT |  | GEVA | Synageva BioPharma announces 6 month data from extension study of SBC-102
Synageva BioPharma announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase, LAL, Deficiency at the American Association for the Study of Liver Diseases, AASLD, annual meeting being held in Boston, MA, November 9-13. |
|
|
News For GEVA From The Last 14 Days Check below for free stories on GEVA the last two weeks. |
|
|
| May 16, 2013 |
| 08:28 EDT |  | GEVA | Synageva has a conference call hosted by JPMorgan
 Subscribe for More Information |
|
| May 10, 2013 |
| 08:05 EDT |  | GEVA | Synageva downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Synageva citing concerns that the enrollment could be challenging for the sebelipase alfa Phase 3 trial. The firm lowered its price target for shares to $50 from $57. |
|
| May 9, 2013 |
| 07:15 EDT | | GEVA | Synageva's sebelipase alfa shows sustained effects and treatment tolerance
Subscribe for More Information |
|
| May 7, 2013 |
| 16:23 EDT | | GEVA | Synageva to initiate natural history study of SBC-103 by mid-year
Subscribe for More Information |
|
| 16:21 EDT |  | GEVA | Synageva reaffirms FY13 net operating loss view ($97M)-($87M)
Subscribe for More Information |
|
| 16:20 EDT | | GEVA | Synageva reports Q1 EPS (54c), consensus (70c)
Reports Q1 revenue $5.12M, consensus $2.56M. |
|
|
|
|
|
